BioRestorative Therapies to Share Q1 2025 Financial Insights
BioRestorative Therapies Set to Announce Q1 2025 Financial Results
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a pioneer in regenerative medicine, is eager to unveil its financial results for the first quarter of 2025. This announcement is scheduled for after market close on a day in mid-May 2025. Following this release, the company's management will host a conference call aimed at discussing these financial updates alongside providing a comprehensive business overview.
Key Details of the Conference Call
The details for participating in the financial results conference call are as follows:
Date
Scheduled for a Wednesday in mid-May 2025.
Time
The call will commence at 4:30 p.m. ET.
Dial-In Information
For domestic participants, the call can be accessed via 1-888-506-0062, while international attendees can join using 1-973-528-0011, with an access code of 924151.
Live Broadcast and Accessibility
This important call will also be broadcast live online and available for later listening on the BioRestorative website, specifically in the Investors section where the latest news and events are regularly updated.
About BioRestorative Therapies, Inc.
Founded with a vision to innovate in regenerative medicine, BioRestorative specializes in therapeutics utilizing adult stem cells. Their dedication hinges on two principal clinical development platforms: the treatment of disc and spine diseases and addressing metabolic disorders. Additionally, the company operates a BioCosmeceuticals platform that emphasizes aesthetic applications.
Disc and Spine Program (brtxDISC™)
The flagship therapy of BioRestorative, BRTX-100, utilizes cultured mesenchymal stem cells derived from a patient’s bone marrow. This product aims to offer relief for individuals suffering from severe lumbosacral disc disorders without resorting to surgery. The team has actively transitioned into a Phase 2 clinical trial, assessing the efficacy of BRTX-100 in managing chronic lower back pain due to degenerative disc disease. FDA clearance has also been acquired for evaluating this treatment for chronic cervical discogenic pain.
Metabolic Program (ThermoStem®)
This innovative program is dedicated to the exploration of cellular therapies to combat obesity and various metabolic disorders. BioRestorative investigates the potential of brown adipose-derived stem cells in generating brown adipose tissue. This approach aims to boost metabolic activity and manage conditions related to obesity and diabetes by mimicking natural biological processes that optimize energy expenditure.
Commercial BioCosmeceuticals
The BioCosmeceuticals division of BioRestorative aims to provide advanced products designed to improve cosmetic appearance and well-being. The formulation of their current serums involves environmentally controlled processes to ensure high-quality outputs, targeting aging signs such as fine lines and wrinkles. Future aspirations include expanding their line-up to introduce more cell-based aesthetic products, all while seeking FDA approvals.
Investors and Contact Information
For those eager to learn more or have inquiries regarding BioRestorative’s future and present performance, Stephen Kilmer from Investor Relations is available at (646) 274-3580. Additionally, interested parties can reach out via email for further discussions.
Frequently Asked Questions
When will BioRestorative announce their Q1 2025 financial results?
BioRestorative will announce their financial results shortly following market close on a Wednesday in mid-May 2025.
How can I participate in the Q1 conference call?
You can join the call using the relevant domestic or international phone numbers provided in the press release, along with the access code.
What therapeutic areas does BioRestorative focus on?
BioRestorative focuses on therapies related to disc/spine diseases and metabolic disorders, leveraging the capabilities of adult stem cells to address these challenges.
What is BRTX-100?
BRTX-100 is BioRestorative’s leading cell therapy designed for the treatment of lumbosacral disc disorders, utilizing the patient's own stem cells.
How can I find updates about BioRestorative?
To stay informed, visit BioRestorative’s official website, particularly the Investors section, for the latest news and event updates.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
